MedImmune, Inc. (Nasdaq: MEDI) announced today that it has filed an investigational new drug application (IND) with the U.S. Food and Drug Administration (FDA) to begin human clinical testing of a cell culture-based seasonal influenza vaccine using its proprietary live, attenuated, needle-free influenza vaccine technology. [click link for full article]
More...